Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
1,413,841 | 1,373,554 | 1,407,351 | 1,292,014 | 1,326,010 |
Cost of Goods Sold (COGS) incl. D&A |
184,776 | 192,371 | 191,394 | 173,758 | 190,504 |
COGS excluding D&A |
87,900 | 98,168 | 100,770 | 89,813 | 101,783 |
Depreciation & Amortization Expense |
96,876 | 94,203 | 90,624 | 83,945 | 88,721 |
Gross Income |
1,229,065 | 1,181,183 | 1,215,957 | 1,118,256 | 1,135,506 |
SG&A Expense |
721,158 | 603,848 | 631,326 | 656,051 | 622,850 |
Research & Development |
345,181 | 304,217 | 329,559 | 355,962 | 338,934 |
Other SG&A |
375,977 | 299,631 | 301,767 | 300,089 | 283,916 |
Other Operating Expense |
77,944 | 75,545 | 78,511 | 85,894 | 72,052 |
Unusual Expense |
6,629 | 6,159 | -14,703 | 6,341 | 21,901 |
Non Operating Income/Expense |
14,383 | 37,871 | -15,350 | 15,444 | 2,227 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
13,400 | 8,700 | 7,000 | 7,400 | 7,500 |
Gross Interest Expense |
23,100 | 15,300 | 15,600 | 7,400 | 15,800 |
Pretax Income |
431,217 | 530,702 | 508,673 | 384,514 | 405,130 |
Income Tax |
136,341 | 131,044 | 121,021 | 82,148 | 104,920 |
Equity in Affiliates |
-2,749 | -1,258 | -511 | 0 | 0 |
Consolidated Net Income |
292,127 | 398,400 | 387,141 | 302,366 | 300,210 |
Minority Interest Expense |
0 | 0 | 295 | -295 | -28 |
Net Income |
292,127 | 398,400 | 386,846 | 302,661 | 300,238 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
292,127 | 398,400 | 386,846 | 302,660 | 300,238 |
Preferred Dividends |
0 | 0 | 0 | 0 | -100 |
Net Income available to Common |
292,127 | 398,400 | 386,846 | 302,661 | 300,338 |
Operational EPS |
1.24 | 1.69 | 1.56 | 1.27 | 1.29 |
EPS (basic) |
1.23 | 1.68 | 1.62 | 1.26 | 1.24 |
EBITDA |
526,839 | 595,993 | 596,744 | 460,256 | 529,325 |
Depreciation & Amortization Expense |
96,876 | 94,203 | 90,624 | 83,945 | 88,721 |
Common Shares Outstanding |
239,740 | 238,125 | 240,622 | 241,828 | 245,033 |
Basic Shares Outstanding |
237,938 | 236,474 | 238,988 | 239,754 | 242,395 |
Diluted Shares Outstanding |
239,740 | 238,125 | 240,622 | 241,828 | 245,033 |
Diluted EPS after Extraordinary Items |
1.22 | 1.67 | 1.61 | 1.25 | 1.22 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
1.23 | 1.68 | 1.62 | 1.26 | 1.23 |
*Figures in thousands of U.S. Dollars except shares outstanding.
